News – Page 993 – Endpoints News

Walking the walk, Alnylam appoints former FDA head Margaret Hamburg to the board

7 years ago

Drop in clinical trial numbers underscores drugmakers' fears over Brexit that trace back over a year

7 years ago

Novartis builds its case for a new sickle cell drug, eyeing a delayed FDA filing in ‘19

7 years ago

Versant-backed Gotham Therapeutics launches with $54M round and a new way to connect on mRNA

7 years ago

Exclusive: At Hal Barron’s R&D group at GSK, consensus is out, leaders are in and watch out for an ‘intense ...

7 years ago

Novartis plans to open a string of global digital labs; Rgenix snags a $40M round in push toward PhII

7 years ago

New Pfizer CEO Albert Bourla shakes up the top team that will now lead the pharma giant -- and there's a chief ...

7 years ago

MIT spinout from Sangeeta Bhatia’s lab gets a $22M round to develop new disease and drug sensors

7 years ago

Trevena crushed as analysts count red flags in FDA’s review of its new pain med

7 years ago

Checkpoint therapies before surgery? MD Anderson team reports encouraging efficacy but worries about toxicity

7 years ago

As CRISPR emerges, researchers spotlight positive effects in prenatal gene editing treatment for mice

7 years ago

5AM partners set a wakeup call for biotech Fund VI, shooting for a record $350M

7 years ago

One of Affimed’s new glass slippers cracks as a deadly incident forces halt to PhI cancer trials

7 years ago

Diurnal stock craters on PhIII fail; Ortho wins tentative FDA OK for Bryhali; Cavion insists failed PhII study was a ...

7 years ago

Reorganization of OND to support new drug review modernization, Woodcock says

7 years ago

Novartis bets PRV on its next big multiple sclerosis drug — eyes US, EU approvals in '19

7 years ago

Menlo’s solo pipeline drug suffers another ugly trial failure, done in by an outperforming placebo

7 years ago

Spark's CSO is wrapping up animal studies on a gene therapy for Pompe disease as new work in the field sees explosive ...

7 years ago

Cancer drug rivals at Loxo and Blueprint go toe-to-toe once again, and one analyst scores a (possible) win on points

7 years ago

Ionis and Akcea get their shot at competing with Alnylam for a rare disease group — but it’s not expected to be ...

7 years ago

GSK hands cash and tech to a biotech startup pointed down the same R&D road they want to travel

7 years ago

Bluebird says EMA has begun reviewing its LentiGlobin gene therapy; Sarepta bags rights to neuropathy gene therapy

7 years ago

Belgian upstart Rewind taps Ian Reynolds as CEO; Robert Foster takes the reins at ContraVir

7 years ago

Xencor’s lead drug fails a PhII test for lupus, shares slide

7 years ago

First page Previous page 990 991 992993994 995 996 Next page Last page